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ABSTRACT:
As an oncogenic transcription factor, the Forkhead box protein M1 (FOXM1) is 
overexpressed in human tumors. FOXM1 promotes tumorigenesis by regulating 
genes associated with cell cycle progression and cell proliferation, and its inhibition 
in cell lines  has been shown to sensitize cells to apoptosis. In this report, we 
examined the possibility of suppressing FOXM1 in tumors in vivo, through the 
administration of FoxM1-specific siRNA. Firstly, we determined the functionality of 
siRNA treatment in subcutaneous MDA-MB-231-luc breast cancer tumors. We found 
that  upon  encapsulation  into  a  PEI-based  delivery  agent,  fluorescently-labeled 
siRNA was retained within tumors when administered intratumorally. Injection of 
anti-luciferase siRNA was also able to suppress tumor-associated luciferase for at 
least 48 hours. More importantly, repeat administrations of PEI-encapsulated anti-
FoxM1 siRNA resulted in the reduced expression of FOXM1 protein levels in tumors. 
In addition, both the protein levels and mRNA levels of cdc25B and Aurora B Kinase, 
transcriptional targets of FOXM1 were also reduced in tumors treated with anti-FoxM1 
siRNA. p27, an indirect target of FOXM1 associated with growth inhibition was further 
found be increased in tumors treated with FoxM1-siRNA. Our data suggests that anti-
FoxM1 siRNA can be functional when administered into tumors in an in vivo system, 
and that anti-FoxM1 siRNA holds potential as part of a therapy for cancer treatment.
INTRODUCTION
The Forkhead box protein M1, FOXM1, serves as 
a transcription factor for a wide range of genes relating 
to cell proliferation, cell cycle progression, adult tissue 
homeostasis, repair of DNA damage, and angiogenesis 
[1-4]. FOXM1 is also considered to be an oncogenic 
transcription factor, as its expression in cancer cells is 
found to be abnormally high [5-10]. In fact, genomic 
studies have identified FoxM1 to be one of the highest 
expressed genes in a wide range of human tumors [5, 11, 
12], where a correlation between tumor aggressiveness 
and FOXM1 expression levels have been shown [8, 9, 13]. 
FOXM1’s role in tumorigensis is based on its regulation 
of cell cycle progression, particularly the G1/S and 
G2/M transition and M phase progression. For example, 
FOXM1 has been found to regulate cell cycle-associated 
genes such as the centrosome proteins CENPA, CENPB 
and CENPF, Cdc25B, cyclin B, Aurora B kinase, survivin, 
and polo-like kinase 1 (PLK1) [7, 14-19]. Consequently, 
several of such genes are also overexpressed in cancers, 
and contribute to the progression of cancer development. 
Furthermore, FOXM1 also negatively regulates the 
expressions of cyclin-dependent kinase inhibitors p21 
and p27, through transcription regulation of Skp2 and 
Cks1 [3, 20]. In addiiton, in vitro studies have shown that 
the suppression of FOXM1 by siRNA sensitizes cancer 
cells to cell death upon stimulation with conventional 
chemotherapeutic drugs [21-23].
Currently, the implementation of RNAi for in vivo 
purposes is challenging, especially in the development 
of nanoparticle carriers for the transportation of siRNA 
to tumors. Examples of successful delivery of siRNAs to 
tumors are widely documented in literature, although few Oncotarget 2011; 2:   1218 - 1226 1219 www.impactjournals.com/oncotarget
have been developed to the stage of clinical applicability 
[24-26]. Recently, demonstrated is the engineering of 
a cyclodextrin-based nanoparticle system, which was 
shown to successfully aid the delivery of anti-RRM2 (M2 
subunit of ribonucleotide reductase) siRNA to melanoma 
cancers in human patients [27]. As research in tumor-
targeted siRNA delivery steadily advances, we examine 
the functional ability of anti-FoxM1 siRNA to induce 
suppression of FOXM1 in tumors, as a proof-of-principle 
for the potential of anti-FoxM1 siRNA as a therapeutic 
agent. 
RESULTS AND DISCUSSION
PEI-encapsulated siRNA is retained in tumor 
xenografts for a minimum of 24 hrs upon 
intratumoral administration
Here, we chose a polyethylimine-based cationic 
poymer, JetPEI (Polyplus) as an encapsulation agent 
for the in vivo delivery agent for siRNA. JetPEI was 
complexed at an N-to-P ratio of 8, with the siRNAs: anti-
FoxM1-siRNA, control siRNA and control-FITC siRNA. 
N refers to the number of positively charged amine groups 
in PEI and P represents the number of negatively charged 
phosphates in the siRNA backbone. Due to the nature of 
Figure 1: PEI-encapsulated siRNA is retained in tumors and is functional for protein suppression. A, Fluorescently-labeled 
siRNA, when encapsulated into JetPEI delivery agents, can be retained in subcutaneous xenograft tumors upon intratumoral delivery for 
at least 24 hours, as determined by the persistence of tumor-associated fluorescence. B, Suppression of tumor-associated luciferase was 
apparent 24 hours post-injection of luciferase-specific siRNA (10µg) and was maintained for at least 48 hours. Tumor-associated luciferase 
continued to increase in control siRNA-treated tumors. C, Quantification of flux (photons/sec) in tumors treated with luciferase-specific and 
control siRNA. n=2-4 tumors, where values depict averages and error bars represent SD.
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PEI-siRNA complexes (overall cationic in zetapotential, 
no protective ‘stealth’ layer), intravenous injection would 
not result in its accumulation into subcutaneous tumors 
[28-30]. The only injection method for successful delivery 
to such tumors would be direct intratumoral injection. 
PEI-encapsulated Fluorescent-siRNA (control 
sequence) was first used to visualize the retention of siRNA 
within subcutaneous xenograft tumors upon intratumoral 
delivery. MDA-MB-231-luc xenografts were prepared 
in nude mice, after which 10µg of siRNA (encapsulated 
with  1.6µL  of  JetPEI)  was  administered  to  tumors 
intratumorally.  The  siRNA-associated  fluorescence  in 
the mice was monitored by whole-body live fluorescence 
imaging,  using  an  excitation  wavelength  of  λ=465nm 
and an emission wavelength of λ=550nm. We found that 
PEI-encapsulated siRNA was retained within tumors 
for at least 24 hours, as determined by the retention of 
tumor-associated  fluorescence  over  time  (Figure  1, A). 
This demonstrates that PEI-encapsulated siRNA can be 
retained in tumors and potentially can induce its functional 
effect upon intratumoral injection.
Presently, methods for the functional delivery 
of siRNA to tumor sites as a means for cancer therapy 
remain limited. The phosphate backbone renders siRNA 
to be negatively charged, a nature that prevents its cellular 
internalization, through electrostatic repulsion with 
negatively charged cell membranes [31]. In addition, 
siRNA is vulnerable to digestion by RNAase enzymes, 
if administered to biological systems without an exterior 
carrier [28, 29]. Required, therefore, are carrier systems 
that can transport siRNA to tumor sites before its action 
on protein suppression can be realized. The development 
of nanomaterials for such purposes has attracted 
considerable attention and since, the successful delivery 
of siRNA to melanoma cancers by intravenous injection 
has been shown in humans [27]. As the delivery of siRNA 
to tumors becomes a clinical reality, researchers have 
relied on adopting the method of intratumoral injection 
to examine the feasibility of suppressing specific proteins 
as part of a chemotherapeutic treatment [29, 30, 32, 33]. 
PEI-encapsulated anti-luciferase siRNA inhibits 
luciferase expression in luciferase-expressing 
tumors
To further elucidate the functional suppression of 
siRNA-specific  proteins  in  such  tumors,  a  non-evasive 
method involving MDA-MB-231-luc (luciferase-
expressing) xenograft tumors and anti-luciferase siRNA   
(siLuc) was firstly adopted. PEI-complexed anti-Luciferase 
siRNA was injected intratumorally into luciferase-
expressing tumors and the tumor-associated-luciferase 
expression was monitored by bioluminescence imaging 
(Figure 1, B, C). It was found that luciferase suppression 
by anti-luciferase siRNA was apparent 24 hours after 
injection, followed by a slow recovery of luciferase 
levels to that of control-treated tumors (Figure 1, B, C). 
Administration of control siRNA (siCon) had no effect on 
luciferase expression in MDA-MB-231-luc tumors, where 
the bioluminescence increased steadily overtime. Here, 
we show that the JetPEI-siRNA formulation is capable 
of inducing protein-specific suppression in tumors, and 
is therefore useful for the administration of therapeutic 
siRNAs. It should be considered that the duration of protein 
suppression depends on both the half-life of the targeted 
protein plus the proliferation rate of the cells; however, the 
time frame of 24-48hrs provides a guideline for intervals 
in a dosing schedule for repeat siRNA administration. It is 
acknowledged that intratumoral injection of siRNA is not 
the preferred method for in vivo RNAi experimentation, 
but here it is unavoidable until tumor-targeted systemic 
administrations of such drugs are fully developed. 
In vitro suppression of FOXM1 and its targets in 
MDA-MB-231-luc cells by anti-FoxM1 siRNA
The effects of anti-FoxM1 siRNA (siFox) on 
the expression of FOXM1 and FOXM1’s targets 
were examined in MDA-MB-231-luc cells in vitro. In 
conjunction with FOXM1 suppression, anti-FoxM1 
siRNA was also able to inhibit the expression of FOXM1 
transcriptional targets (Figure 2, A, B). Specifically, the 
protein levels of Aurora B Kinase and cdc25B were 
found to be suppressed after a 48 hr treatment with anti-
FoxM1 siRNA (Figure 2, A). Additionally, reductions in 
mRNA levels of FOXM1’s transcriptional targets were 
also observed, upon transfection with anti-FoxM1 siRNA 
(Figure 2, B). As targets of FOXM1 are also associated 
with cell proliferation, they too are being pursued as 
potential targets for cancer treatment. Examples include 
drugs such as HQPA (hydroxyquinazoline pyrazol 
anilide) and NSC663284 [6-chloro-7-(2-morpholin-4-
ylethylamino)quinoline-5,8-dione], small molecules 
used for the inhibition Aurora B Kinase and cdc25B, 
respectively [34-38]. In this case, the effect of FOXM1 
suppression is likely similar to the effect of inhibiting 
individual FOXM1 targets, as suppression of proteins 
further upstream of molecular pathways may lead to the 
suppression of a range of targets that contribute to cancer 
cell viability. Additionally, p27, a non-direct, secondary 
target of FOXM1 was found to be up-regulated by 
FOXM1 suppression, because of the down-regulation of 
Skp2, a component of the SCF-Skp2 ubiquintin ligase that 
targets 27 for proteolytic degradation (Figure 2, A) [3, 20]. 
This suggests that the reduction of the protein levels of 
FOXM1’s targets is through suppression of their mRNA 
transcription. 
We  further  demonstrated  the  applicability  of 
JetPEI to act as a delivery agent of siRNA, shown by 
the induced suppression of FOXM1 in MDA-MB-231 Oncotarget 2011; 2:   1218 - 1226 1221 www.impactjournals.com/oncotarget
cells upon treatment with JetPEI-complexed anti-FoxM1 
siRNA (Figure 2, C). The inhibition of FOXM1 protein 
expression by JetPEI-siRNA was maintained for at least 
48hrs, whilst treatment with controls (JetPEI complexed 
with non-functional control siRNA, siCon) had no effect 
on FOXM1 expression (Figure 2, C). 
FOXM1, with its roles in cell proliferation, along with 
its overexpression cancer cells, is becoming increasingly 
highlighted as a drug target for cancer therapy. Molecules 
such as ARF-peptide [39], thiazole antibiotics thiostrepton 
and Siomycin A [40-42], proteasome inhibitors in general 
[43] and other small molecules [44] have been shown to 
be suppressors of FOXM1 in vitro and in vivo. However, 
such drugs, particularly the proteasome inhibitors, are 
likely to operate through multiple mechanisms that may 
affect numerous proteins, not just that of FOXM1 [43, 
44]. On the other hand, siRNA is known to selectively 
inhibit target proteins, therefore inhibition of FoxM1 by 
anti-FoxM1 siRNA will be specific way to target FOXM1. 
Repeat intratumoral injection of PEI-
encapsulated anti-FoxM1 siRNA suppresses the 
expression of FOXM1 and its targets in MDA-
MB-231-luc tumor xenografts
MDA-MB-231-luc cells were implanted 
subcutaneously into the flanks of nude mice and allowed 
to proliferate until tumors reached sizes of ~200mm3. 
JetPEI-encapsulated anti-FoxM1 siRNA was prepared and 
administered intratumorally to tumors at a dose of 10µg 
siRNA/tumor, once every other day (3-4 times per week). 
Control tumors received intratumoral injections of JetPEI 
only, as previous experiments showed that control siRNA 
had no effect on protein expression (Figure 1, B and Figure 
2, A). After 10 injections (20 days), tumors were removed 
and analyzed for protein and mRNA levels of FOXM1, 
Aurora B Kinase, cdc25B and appropriate controls. We 
found that the protein levels of FOXM1 were effectively 
Figure 2: FoxM1-specific siRNA (siFox) suppresses the expression of FOXM1 and its targets in MDA-MB-231-luc 
cells. A, siFox (50nM, delivered via Lipofectamine2000, 48 hours post-transfection) suppresses the protein levels of FOXM1 and its direct 
transcriptional targets Aurora B Kinase and cdc25B, and elevates levels of an indirect target of p27. B, siFox (50nM) inhibits the mRNA 
levels of Aurora B Kinase and cdc25B. n=3, values depict averages and error bars represent SD. C, JetPEI-encapsulation of siFox (50nM) 
is also functional in suppression FOXM1 and is therefore feasible as a delivery agent to tumors.
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reduced in tumors treated with repeat administration of 
siFox siRNA, compared to that of control-treated tumors 
(Figure 3, A). Complying with in vitro results, protein 
levels of Aurora B Kinase (Figure 3, A) and cdc2B 
(Figure 3, A) were also found to be suppressed in tumors 
treated with siFox siRNA. Again, the mRNA levels of 
the FoxM1 targets were consistently reduced in tumors 
subjected to siFox injections (Figure 3, B). A reduction in 
FOXM1, Aurora B Kinase and cdc25B also corresponded 
to an increase in levels of p27, the cyclin-dependent 
kinase inhibitor that is indirectly negatively regulated by 
FOXM1 (Figure 3, A). These findings suggest that the 
injection of PEI-encapsulated siRNA is functional in such 
a tumor model, and that FOXM1 suppression also leads to 
the repression of its transcriptional targets.
As FOXM1 is known as a master regulator of the 
cell cycle, its suppression inhibits the transcription of 
genes associated with proliferation and tumor growth, and 
therefore may be beneficial to part of a cancer treatment. In 
conjunction with in vitro studies, suppression of FOXM1 
in tumors by siRNA also realized the suppression of its 
targets. As with our in vivo data, other studies have also 
described the depletion of FOXM1 targets such as cdc25B 
and Aurora B Kinase in FOXM1-null cells [3, 15]. The 
suppression of FOXM1 and its targets also corresponds 
to the upregulation of p27, a Cdk inhibitor protein that 
is negatively regulated on protein level by the FOXM1 
target, Skp2 [39]. Particularly, high FOXM1 expression 
has been found to increase resistance towards certain 
anticancer drugs [21-23], and its inhibition may sensitize 
cancer cells towards current chemotherapeutic drugs. 
If the suppression of FOXM1 by siRNA is feasible and 
efficient in mouse tumor models, it may pave way for 
the development of RNAi-based therapies for FOXM1-
targeting in human tumors. 
METHODS
Materials
MDA-MB-231-luc-D3H2-LN, human lymph node-
derived metastatic mammary gland adenocarcinoma 
(Caliper Lifescience) were maintained in MEM media 
Figure 3: Repeat injection of siFox reduces protein expressions of FOXM1 and its targets in MDA-MB-231-luc 
subcutaneous tumors. A, After 10 intratumoral injections of siFox (10µg, complexed with 1.6µL JetPEI, once every two days, over 
20 days), protein levels of FOXM1, Aurora B Kinase and cdc25B were suppressed, compared to tumors treated with JetPEI-only controls. 
Western blots represent 5 individual tumors from each treatment group. B, siFox also reduced the mRNA levels of FOXM1 transcriptional 
targets, as demonstrated by quantitative PCR. n= 5-8 where values depict averages and error bars represent SEM. 
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(Mediatech) supplemented with 10% FBS (Atlanta 
Biological), 1% 100X non-essential amino acids 
(Gibco), 1% 200mM NaPyruvate (Gibco) and 75µg/mL 
Zeocin (Invitrogen). JetPEI and 20% glucose solution 
was obtained from Polyplus, Lipofectamine 2000 was 
purchased from Invitrogen and Optimem was purchased 
from Gibco. Trizol was obtained from Ambion, High 
capacity cDNA Reverse Transcription kit was purchased 
from Applied Biosystems and SYBR Green fast start 
universal was obtained from Roche. All primers were 
synthesized by Integrated DNA Technologies. Anti-
FoxM1 and control siRNAs were purchased from Sigma, 
Fluorescent-siRNA (Allstars Negative Alexa Fluor 488) 
and anti-Luciferase GL3 siRNA were purchased from 
Qiagen. D-Luciferin (potassium salt) was obtained from 
Gold Biotechnology. 
METHODS
Treatment of cells in vitro
MDA-MB-231 cells were seeded at 5x104 cells/3cm 
plate in antibiotic-free media and incubated overnight 
before treatment. siRNA was complexed with either 
Lipofectamine2000 or with JetPEI before administration 
to cells. For complexation with Lipofectamine2000: in 
one vial, 1.5µL siRNA (100µM in nuclease-free H2O) was 
diluted in Optimem (50µL), and in another vial, 2.25µL 
of Lipofectamine2000 was diluted in Optimem (50µL). 
The Lipofectamine2000 solution was added to the siRNA 
solution and mixed by pipetting. The siRNA/liposome 
complexes were incubated at room temperature for 
10mins before administration to cells at 50nM (1.5nmol 
siRNA per plate containing 3mL antibiotic-free media). 
Cells were incubated with Lipofectamine-siRNA for 48 
hours before collection for analysis. For complexation 
with  JetPEI:  in  one  vial,  1.5uL  of  siRNA  (100µM  in 
nuclease-free H2O) was diluted in 25µL of a 10% glucose 
solution (1:1 H2O/10% glucose, v/v, equivalent to a 
5% glucose solution). In another vial, 0.24µL of JetPEI 
was  diluted  in  25µL  of  a  10%  glucose  solution  and 
then added to the siRNA solution. The siRNA-JetPEI 
complex was incubated at room temperature for 10mins 
before administration to cells. Cells were incubated with 
JetPEI-siRNA for 24hrs or 48 hours before collection for 
analysis. Specific siRNA sequences are as follows: FoxM1 
Sense, 5’-GGACCACUUUCCCUACUUUUU-3’, 
FoxM1 Antisense, 
5’-UUAAAGUAGGGAAAGUGGUCC-3’, Control 
Sense, 5’-AACAGUCGCGUUUGCGACUGGUU-3’ 
and Control Antisense, 
5’-UUGUCAGCGCAAACGCUGACC-3’.
Western Blot analysis of cell lysates
Cells were harvested with IP lysis buffer (20mM 
HEPES, 1% Triton X-100, 150mM NaCl, 1mM EDTA, 
1mM EGTA, 100mM NaF, 10mM Na4P2O7, 1mM Na3VO4, 
0.2mM PMSF). For analysis of tissues, liquid N2-frozen 
sections of xenograft tumors were homogenized in 1mL 
IP lysis buffer. Protein concentrations of cell or tumor 
lysates were measured by the Bio-Rad Protein Assay and 
protein separation was performed on 8% or 12% SDS-
PAGE gels. Separated proteins were then transferred onto 
PVDF membranes (Millipore) and immunoblotted with 
specific antibodies against FOXM1 (c-20, Santa Cruz), 
Aurora B Kinase (cell signaling), cdc25B (cell signaling) 
and ß-actin (Sigma) 
Quantitative RT-PCR of cell lysates
Monolayer cells and tumor sections were treated 
with Trizol for RNA isolation. For cells in vitro, media 
was removed from plates and cells were collected after 
addition of 1mL Trizol. For tumors, N2 (l)-frozen sections 
were homogenized (Fisher, Polytron) in 1mL Trizol. After 
treatment with Trizol, RNA was isolated by standard 
methods, comprising of chloroform extraction, precipitation 
with isopropanol, pellet washing with 75% EtOH (in 
H2O) and redissolving in nuclease-free H2O. cDNA was 
synthesized using the SuperScript First Strand Synthesis 
Kit according to the manufacturer’s recommendations 
(Invitrogen). 2µg of cDNA was used with specific primers 
and SYBER-Green I for quantitative analysis of mRNA 
concentrations on an ABI 7900 HT system. Cyclophilin 
mRNA levels were used as normalization controls. 
Primer sequences are as follows: FoxM1 Sense- 5’- 
TCCCTGCTGCCTGATTATGC-3’, FoxM1 Antisense- 
5’- TCACCATTGCCTTTGTTGTTCC-3’, Aurora B 
Kinase Sense- 5’- CTGGAATATGCACCACTTGGA-3’, 
Aurora B Kinase Antisense- 5’- 
CGAATGACAGTAAGACAGGG-3’, cdc25B Sense- 5’- 
CCCTTCCCTGTTTTCCTTTC-3’, cdc25B Antisense- 
5’- ACACACACTCCTGCCATAGG-3’, Cyclophilin 
Sense- 5’- CACCCTGACACATAAACCCTGG-3’, 
Cyclophilin Antisense- 5’- 
GCAGACAAGGTCCCAAAGACAG-3’.
Animal maintenance and tumor xenograft 
experiments
Animals were maintained and treated in accordance 
with the guidelines established by the Animal Care and 
Use Committee of UIC. Tumor models were prepared 
by implanting cancer cell lines (1x106 of MDA-MB-
231-luc), suspended in 50uL of 1:1 PBS/Matrigel into 
each flank of 4-week old male athymic mice (Taconic). Oncotarget 2011; 2:   1218 - 1226 1224 www.impactjournals.com/oncotarget
Treatment began once tumors reached sizes of 200mm3. 
After completion of the dosing schedule, animals were 
sacrificed and tumors were removed. Tumors were sliced 
in half and either frozen in liquid N2 or fixed overnight in 
10% formalin (4ºC). Frozen tumors were then sliced and 
homogenized in 1mL of either IP lysis buffer, or in Trizol, 
or western blot and RT-PCR analysis, respectively.
Tumor-retention of fluorescent-siRNA 
To study the retention of JetPEI-siRNA (AF488) in 
MDA-MB-231-luc xenograft tumors, 10µg Fluorescent-
siRNA  (encapsulated  with  1.6µL  JetPEI  in  50uL  5% 
glucose solution by method described before) was 
injected  directly  into  tumor  tissues  (50µL  per  tumor). 
Animals were anaesthetized under isofluorane and imaged 
for whole-body fluorescence (ex= 465nm, em=550nm) at 
0hr, 12hr and 24hr post-administration using the Xenogen 
IVIS imaging system.
Treatment of tumors with functional siRNA (anti-
luciferase and anti-FoxM1)
Anti-luciferase and anti-FoxM1 siRNA were 
administered to MDA-MB-231-luc subcutaneous tumors 
(200mm3)  at  10µg  per  tumor  (complexed  with  1.6µL 
JetPEI in 50µL of 5% glucose solution). For Luciferase 
experiments, tumors were injected with either anti-
Luciferase siRNA or control siRNA, after which tumor-
associated  fluorescence  was  monitored  by  whole  body 
bioluminescence imaging. To do so, animals were 
injected with 100mg luciferin/kg 10 mins before animals 
were  anaesthetized  under  isoflurane.  Tumor-associated 
bioluminescence were recorded on a Xenogen IVIS 
imaging system and quantified as flux (photon/sec) using 
the Living Image Software. 
For functional suppression of FOXM1, anti-FoxM1 
siRNA/JetPEI (10µg in 5µL 5% glucose solution) was 
administered to tumors 3 times a week for 3 weeks (total 10 
injections, 50µL per injection). Control animals were treated 
with JetPEI only (1.6µL per tumor, 50uL per injection). 
After the treatment schedule, animals were euthanized 
and tumors removed and frozen in liquid N2. siRNA 
sequences for anti-FoxM1 and control siRNAs are stated 
above and those for anti-luciferase siRNA are as follows: 
Sense- 5’-r(CUUACGCUGAGUACUUCGA)d(TT)-3’ 
and Antisense- 5’-r(UCGAAGUACUCAGCGUAAG)
d(TT)-3’.
CONCLUSIONS
In this report, we describe the effect of administering 
anti-FoxM1 siRNA into MDA-MB-231-luc breast cancer 
tumors. Firstly, we show that intratumoral injections of 
PEI-encapsulated siRNA was able to be retained within 
tumors, and secondly, we demonstrate its ability to induce 
a  specific  protein  suppression  effect.  Furthermore,  we 
show that the intratumoral injection of FoxM1-specific 
siRNA is able to suppress the protein expression of 
FOXM1, along with the protein and gene expressions 
of its transcriptional targets. These results showcase the 
effect of anti-FoxM1 siRNA in tumors, and highlight the 
potential of FOXM1-targeting as part of a cancer therapy.
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